Example: Heart Attack

Clinical Trials on Neurofibroma, Plexiform

Total 48 results

NCT04495127

Recruiting

Selumetinib Paediatric NF1 Japan Study

Conditions: Neurofibromatosis Type 1
NCT04212351

Recruiting

Frameshift Peptides of Children With NF1

Conditions: Neurofibromatosis Type 1
NCT03975829

Recruiting

Pediatric Long-Term Follow-up and Rollover Study

Conditions: Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneurona Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Liponeurocytoma; Neurofibromatosis Type 1
NCT03962543

Recruiting

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Conditions: Plexiform Neurofibroma; Neurofibromatosis Type 1 (NF1)
NCT03820778

Enrolling by invitation

Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1

Conditions: Neurofibromatosis 1; Neurofibroma; Atypical Neurofibroma; Atypical Neurofibromatosis; Plexiform Neurofibroma; Von Recklinghausen Disease
NCT03741101

Recruiting

Treatment of NF1-related Plexiform Neurofibroma With Trametinib

Conditions: Neurofibromatosis 1; Child; Neurofibroma, Plexiform
NCT03688568

Recruiting

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Conditions: Neurofibroma, Plexiform
NCT03649165

Completed

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

Conditions: Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs); Healthy Participants
NCT03531814

Recruiting

Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials

Conditions: Neurofibromatosis 1; Neurofibroma, Plexiform
NCT03363217

Recruiting

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Conditions: Low-grade Glioma; Plexiform Neurofibroma; Central Nervous System Glioma
NCT03326388

Recruiting

Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours

Conditions: Neurofibromatosis Type 1; Plexiform Neurofibroma; Optic Nerve Glioma
NCT03259633

Approved for marketing

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

Conditions: NF type1 With Inoperable Plexiform Neurofibromas
NCT03231306

Recruiting

Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

Conditions: Neurofibromatosis Type 1; Plexiform Neurofibroma
NCT03109301

Withdrawn

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Conditions: Neoplasms, Nerve Tissue; Neurofibromatosis 1; Heredodegenerative Disorders, Nervous System; Peripheral Nervous System Diseases
NCT03027401

Not yet recruiting

Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics

Conditions: Neoplasms; Adenomatous Polyposis Coli; Neurofibroma, Plexiform; Myelodysplastic Syndromes
NCT02777775

Unknown status

Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.

Conditions: Cutaneous Neurofibromas; Neurofibromatosis Type 1; Plexiform Neurofibromas
NCT02544022

Recruiting

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)

Conditions: Neurofibromatosis 1; Plexiform Neurofibromas
NCT02471339

Active, not recruiting

Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain

Conditions: Neurofibromatosis Type 1; Plexiform Neurofibromas
NCT02407405

Recruiting

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Conditions: Neurofibromatosis 1; Plexiform Neurofibromas (PN)
NCT02390752

Recruiting

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

Conditions: Neurofibroma, Plexiform; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Prolymphocytic, Acute; Sarcoma
NCT02211768

Completed

Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

Conditions: Neurofibromatosis; MPNST
NCT02177825

Terminated

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Conditions: Plexiform Neurofibromas
NCT02124772

Active, not recruiting

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Conditions: Cancer
NCT02101736

Recruiting

Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults

Conditions: NF1; Neurofibromatosis; Plexiform Neurofibromas
NCT02096471

Completed

MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1

Conditions: Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
NCT01800032

Active, not recruiting

PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)

Conditions: Neurofibromatosis-1; Optic Glioma; Plexiform Neurofibroma
NCT01673009

Completed

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Conditions: Neurofibromatosis
NCT01412892

Completed

Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas

Conditions: Neurofibromatosis Type 1; Plexiform Neurofibroma; Neurofibromatoses
NCT01402817

Terminated

Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas

Conditions: Neurofibromatosis; NF1; Plexiform Neurofibromas
NCT01365468

Terminated

Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

Conditions: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
NCT01362803

Active, not recruiting

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Conditions: Neurofibromatosis 1; Neurofibromatosis Type 1; NF 1; Neurofibroma, Plexiform
NCT01275586

Completed

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Conditions: Neurofibromatosis; NF1; Neurofibromas
NCT01140360

Completed

Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas

Conditions: Neurofibromatosis; Neurofibromas
NCT00924196

Recruiting

Natural History Study of Patients With Neurofibromatosis Type I

Conditions: Neurofibromatosis Type 1; Malignant Peripheral Nerve Sheath Tumor; Plexiform Neurofibroma; Optic Glioma; Neurofibroma
NCT00754780

Completed

Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1

Conditions: Neurofibromatosis
NCT00727233

Completed

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Conditions: Neurofibromatosis Type I; Plexiform Neurofibroma
NCT00716469

Terminated

Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas

Conditions: Neurofibroma
NCT00634270

Completed

A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Conditions: Neurofibromatosis Type 1
NCT00396019

Completed

Study of PEG-Intron for Plexiform Neurofibromas

Conditions: Plexiform Neurofibroma
NCT00340522

Completed

Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development

Conditions: Cancer
NCT00326872

Terminated

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Conditions: Neurofibromatosis Type 1; Plexiform Neurofibroma; Spinal Cord Neurofibroma
NCT00253474

Completed

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

Conditions: Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
NCT00076102

Completed

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

Conditions: Neurofibromatosis 1; Neurofibroma, Plexiform
NCT00060008

Terminated

Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma

Conditions: Neurofibromatosis Type 1; Precancerous Condition
NCT00053937

Completed

Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas

Conditions: Neurofibromatosis Type 1; Precancerous Condition
NCT00030264

Completed

Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas

Conditions: Neurofibromatosis Type 1; Precancerous Condition
NCT00021541

Completed

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Conditions: Neurofibroma, Plexiform; Neurofibromatosis Type I
NCT00006435

Completed

Study of Plexiform Neurofibromas in Neurofibromatosis Type 1

Conditions: Plexiform Neurofibromas; NF1

COOKIE SETTINGS

Clinical Trials on Neurofibroma, Plexiform